Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
Stavenhagen
Jeffrey B
JB
MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850, USA. stavenhagenj@macrogenics.com
Gorlatov
Sergey
S
Tuaillon
Nadine
N
Rankin
Christopher T
CT
Li
Hua
H
Burke
Stephen
S
Huang
Ling
L
Johnson
Syd
S
Koenig
Scott
S
Bonvini
Ezio
E
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000235:genetics; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000502:physiology*; D007074:Immunoglobulin G / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D015202:Protein Engineering; D011961:Receptors, Fc / Q000502:physiology*; D017452:Receptors, IgG / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000378:metabolism
D000911:Antibodies, Monoclonal; C080571:Fc gamma receptor IIB; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D011961:Receptors, Fc; D017452:Receptors, IgG; D011993:Recombinant Fusion Proteins